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Introduction: The IRESSA Survival Evaluation in Lung Cancer
(ISEL) phase III study compared the efficacy of gefitinib (IRESSA)
versus placebo in patients with refractory advanced non-small cell
lung cancer (NSCLC). Although a statistically significant difference
in survival was not seen between gefitinib and placebo in the overall
ISEL population, preplanned subset analyses demonstrated a signif-
icant survival benefit in patients who had never smoked and in
patients of Asian origin.
Methods: In ISEL, 1692 patients who were refractory to or intol-
erant of their latest chemotherapy were randomized to receive either
gefitinib (250 mg/day) or placebo, plus best supportive care. Pre-
planned subgroup analyses included an assessment of patients who
were of Asian origin (n  342).
Results: Two hundred thirty-five patients of Asian origin re-
ceived gefitinib, and 107 received placebo. In these patients,
treatment with gefitinib significantly improved survival com-
pared with placebo (hazard ratio [HR], 0.66; 95% confidence
interval [CI], 0.48, 0.91; p 0.010; median survival, 9.5 versus 5.5
months). Patients of Asian origin also experienced statistically
significant improvements in time to treatment failure with gefitinib
compared with placebo (HR, 0.69; 95% CI, 0.52, 0.91; p  0.0084;
4.4 versus 2.2 months), and objective response rates were higher
with gefitinib than with placebo (12 versus 2%). Gefitinib was
generally well tolerated in patients of Asian origin, with rash and
diarrhea being the most common adverse events. No unexpected
adverse events were observed.
Conclusions: Treatment with gefitinib was associated with a signif-
icant improvement in survival in a subgroup of patients of Asian
origin with previously treated refractory advanced NSCLC.
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Lung cancer is the leading cause of cancer-related deathworldwide; it is responsible for over a million deaths per
year and over 400,000 in Eastern Asia alone.1 Indeed, lung
cancer has a high incidence in Eastern Asia compared with
the global population as a whole, with an incidence of 17.7
cases per 100,000 population compared with 12.1 cases per
100,000 population worldwide.1 Current first-line treatment
for advanced non-small cell lung cancer (NSCLC) involves
platinum-based chemotherapy. Until recently, the only sec-
ond-line treatment option available was docetaxel, which
provides median survival of 7.0 months compared with
4.6 months with best supportive care (BSC) alone in a
Western population.2
In 2002, gefitinib (IRESSA), an epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI),3
was approved in Japan for the treatment of inoperable or
recurrent NSCLC. Japan was the first country to approve
the use of gefitinib in any clinical setting. Subsequently,
gefitinib has been approved in a number of countries,
including many across Asia. This approval both in Japan
and worldwide was based on data from two large phase II
trials of gefitinib monotherapy in previously treated pa-
tients with advanced NSCLC (IRESSA dose evaluation in
advanced lung cancer [IDEAL 1 and 2]). The IDEAL trials
showed an antitumor effect, with a median survival rate of
5.9 to 8.0 months.4,5 In IDEAL 1, Japanese patients gained
particular clinical benefit from gefitinib, with tumor re-
sponse rates of 27.5% compared with 18.4% for the overall
IDEAL 1 population. One-year survival rates were also
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higher in Japanese patients from IDEAL 1; 57% in patients
receiving 250 mg gefitinib and 45% in those receiving
500 mg, compared with 35 and 29%, respectively, in the
overall population.4,6 These clinical trial data have been
supported by other gefitinib monotherapy reports in which
patients of Asian origin seem to have benefitted more than
patients of non-Asian origin.7–13
The effect of gefitinib on survival in the advanced
NSCLC setting was further evaluated in a placebo-con-
trolled phase III study (IRESSA Survival Evaluation in
Lung cancer [ISEL]), which included approximately 20%
of patients who were of Asian origin. This study evaluated
either gefitinib (250 mg/day) or placebo plus BSC in
patients with advanced NSCLC who were refractory to or
intolerant of their most recent chemotherapy regimen.14 In
the overall ISEL population, although there was some
increase in survival with gefitinib compared with placebo,
the difference did not reach statistical significance (hazard
ratio [HR], 0.89; 95% confidence interval [CI], 0.77, 1.02;
p  0.087). Median survival was 5.6 versus 5.1 months for
gefitinib and placebo, respectively. However, time to treat-
ment failure (TTF) was significantly improved in the
gefitinib-treatment arm compared with placebo (HR, 0.82;
95% CI, 0.73, 0.92; p  0.001; median TTF, 3.0 versus
2.6 months). There was also a significant improvement in
objective response rate (ORR) with gefitinib compared
with placebo (odds ratio, 7.28; 95% CI, 3.1, 16.9;
p  0.0001; ORR, 8.0 versus 1.3%). Although survival
improvement in the overall ISEL population did not reach
statistical significance, preplanned treatment-by-covariate
interaction analyses revealed that treatment effects (i.e.,
HR) for overall survival differed in patients of Asian
origin compared with non-Asian patients (interaction test
p  0.0430) and in patients who had never smoked
compared with those who had smoked (interaction test
p  0.0474). This enabled valid subgroup analyses to be
performed within these subsets. In this article, we report
our evaluation of the ISEL data for patients of Asian ethnic
origin.
MATERIALS AND METHODS
Trial Design and Participants
The ISEL study (1839IL/709)14 was a double-blind,
placebo-controlled, parallel-group, multicenter, randomized,
phase III study of gefitinib plus BSC in patients with previ-
ously treated, locally advanced, or metastatic NSCLC. The
primary endpoint was survival in the overall and adenocar-
cinoma patient populations. Secondary endpoints were TTF,
ORR, quality of life (QoL), and tolerability.
A total of 1692 patients were enrolled from
210 centers in 28 countries across Europe, Asia, Central
and South America, Australia, and Canada. The subset
analysis described here includes all patients of Asian
origin from the ISEL trial. The definition of patients of
Asian origin excludes those of Indian origin (who were
classified as Caucasian) and refers to the ethnic origin of a
patient’s group, which is not necessarily their place of
birth. For example, individuals of Japanese racial origin
were classed in the Asian race category even if they were
second- or third-generation Australian. Patients of Asian
origin were further classified into five ethnic groups:
Chinese, Japanese, Asian (other than Chinese and Japa-
nese), other, and not applicable (i.e., those who did not
consider themselves as belonging to a specific ethnic
group).
Patients included in the study were aged 18 years or
over, had histologically or cytologically proven locally
advanced or metastatic NSCLC that was not curable with
surgery or radiotherapy, had received one or two prior
chemotherapy regimens, and were refractory or intolerant
to their most recent prior chemotherapy regimen. All
patients had a life expectancy of at least 8 weeks and a
World Health Organization performance status (PS) of 0 to
3. Patients of PS 3 were deemed ineligible if the poor PS
was judged by the investigator to be primarily attributable
to coexisting morbidity. Exclusion criteria included the
presence of small-cell lung cancer either alone or with
NSCLC, untreated or clinically unstable newly diagnosed
metastases in the central nervous system, administration of
the last dose of single-agent chemotherapy within the
previous 14 days or combination chemotherapy within the
previous 21 days, and completion of radiotherapy within
the previous week.14 The study followed the Declaration of
Helsinki15 and good clinical practice guidelines. Trial
approval was obtained from the ethics committee at each
trial center, and all patients provided written, informed
consent.
Treatment
Patients were randomly assigned by the minimization
method16 in a two-to-one ratio to either gefitinib (250 mg/
day) or placebo (double-dummy technique). All patients
received BSC according to the local practice of the individual
institutions and centers and continued to receive study med-
ication until unacceptable toxicity occurred, consent was
withdrawn, or the patient was no longer deriving clinical
benefit. Repeated dose interruptions of up to 14 days were
allowed to manage toxicity.
Procedures
Survival was assessed from the date of randomiza-
tion to the date of a patient’s death. All patients remaining
in the study at data cutoff were censored in the analysis at
the last time they were known to be alive. TTF was
calculated from the date of randomization to the date of
study discontinuation for any reason, and patients who
remained on study therapy at the time of the final analysis
were censored for TTF at their last study visit. Objective
response was defined as all patients with complete or
partial responses; ORR was calculated according to stan-
dard criteria.17 QoL was assessed with the functional
assessment of cancer therapy–lung (FACT-L) question-
naire,18 and disease-related symptoms were assessed every
4 weeks. Changes in disease-related symptoms were classed as
clinically relevant if the lung-cancer subscale score was changed
by at least two points from baseline.18 Adverse events were
monitored at each study visit, graded by the National Cancer
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Institute common toxicity criteria version 2.0,19 and coded ac-
cording to the Medical Dictionary for Regulatory Activities
terminology.20 Routine hematological, clinical chemistry, and
urinalysis assessments were performed at regular intervals. For a
more detailed description of the procedures used in the ISEL
study, see Thatcher et al.14
TABLE 1. Baseline Demographic and Disease Characteristics for Patients of Asian Origin
Gefitinib (n  235) Placebo (n  107) All (n  342)
Median age (yr [range]) 61 (36–90) 61 (39–87) 61 (36–90)
Gender (n [%])
Male 140 (59.6) 64 (59.8) 204 (59.6)
Female 95 (40.4) 43 (40.2) 138 (40.4)
Smoking history (n [%])
Never a smoker 97 (41.3) 44 (41.1) 141 (41.2)
Smoker 138 (58.7) 63 (58.9) 201 (58.8)
Performance status (n [%])
0 39 (16.6) 16 (15.0) 55 (16.1)
1 131 (55.7) 61 (57.0) 192 (56.1)
2 51 (21.7) 22 (20.6) 73 (21.3)
3 14 (6.0) 8 (7.5) 22 (6.4)
Tumor histology (n [%])
Adenocarcinoma 144 (61.3) 65 (60.7) 209 (61.1)
Bronchioalveolara 7 (3.0) 3 (2.8) 10 (2.9)
Squamous cell 55 (23.4) 25 (23.4) 80 (23.4)
Large cell 5 (2.1) 2 (1.9) 7 (2.0)
Mixed 6 (2.6) 3 (2.8) 9 (2.6)
Undifferentiated 17 (7.2) 9 (8.4) 26 (7.6)
Disease stage at diagnosis (n [%])
I 11 (4.7) 7 (6.5) 18 (5.3)
II 4 (1.7) 5 (4.7) 9 (2.6)
IIIa 21 (8.9) 5 (4.7) 26 (7.6)
IIIb 72 (30.6) 30 (28.0) 102 (29.8)
IV 127 (54.0) 60 (56.1) 187 (54.7)
Time from diagnosis (n [%])
6 months 58 (24.7) 34 (31.8) 92 (26.9)
6–12 months 94 (40.0) 41 (38.3) 135 (39.5)
12 months 83 (35.3) 32 (29.9) 115 (33.6)
Current disease status (n [%])
Locally advanced 38 (16.2) 16 (15.0) 54 (15.8)
Metastatic 197 (83.8) 91 (85.0) 288 (84.2)
Number of prior chemotherapy regimens (n [%])
1 126 (53.6) 69 (64.5) 195 (57.0)
2 108 (46.0) 36 (33.6) 144 (42.1)
3 0 (0) 1 (0.9) 1 (0.3)
4 1 (0.4) 1 (0.9) 2 (0.6)
Prior therapy (n [%])
Platinum based 223 (94.9) 101 (94.4) 324 (94.7)
Both platinum based and docetaxel 64 (27.2) 27 (25.2) 91 (26.6)
Reason for failure of last chemotherapy (n [%])
Refractoryb 219 (93.2) 104 (97.2) 323 (94.4)
Intolerant 16 (6.8) 3 (2.8) 19 (5.6)
Best response to most recent chemotherapy (n [%])
Complete/partial response 50 (21.3) 22 (20.6) 72 (21.1)
Stable disease 81 (34.5) 34 (31.8) 115 (33.6)
Progressive disease 82 (34.9) 42 (39.3) 124 (36.3)
Nonevaluable 22 (9.4) 9 (8.4) 31 (9.1)
a Patients with bronchioalveolar carcinoma were included in the adenocarcinoma group for analysis; b refractory defined as recurrent or progressive disease (clinical or
radiological) while receiving or within 90 days of last dose of chemotherapy.
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Statistical Considerations
Preplanned subset analyses in the ISEL trial14 used a
rigorous statistical approach to limit the risk of false-positive
findings in subsets. A treatment-by-covariate interaction was
assessed to ensure that overall survival outcome between
subsets was likely to be different, and further analysis was
only undertaken if this was statistically significant at the 5%
level.
Within the subgroups identified for further analysis,
analyses of overall survival were performed in the intention-
to-treat (ITT) population using a proportional hazards model
including factors for histology, gender, smoking history,
reason for prior chemotherapy failure, number of prior che-
motherapy regimens, and PS. HRs were generated with 95%
CIs and p values. Survival data were displayed graphically
using Kaplan-Meier curves. Further analyses of TTF, ORR,
and QoL were also performed. Formal statistical analyses of
QoL improvement rates and safety data were not preplanned
in the statistical analysis plan and were therefore not per-
formed.
Within the subset of patients of Asian origin, further
exploratory analysis was performed to examine survival in
the following subsets: adenocarcinoma versus nonadeno-
carcinoma, males versus females, never smoked versus
current/former smoker (hereafter referred to as never
smokers versus smokers), refractory versus intolerant, one
versus two prior chemotherapy regimens, PS 0 or 1 versus
PS 2 or 3, age 65 versus 65 years, interval from
diagnosis to randomization 6 versus 6 to 12 versus
12 months, prior docetaxel therapy versus no prior do-
cetaxel therapy, and prior chemotherapy response of com-
plete/partial response versus stable disease versus progres-
sive disease/not evaluated.
RESULTS
Patient Demography
Between July 2003 and August 2004, 342 patients of
Asian origin (primarily from Taiwan, Thailand, Singapore,
the Philippines, and Malaysia) were recruited into the
ISEL study and included in the ITT population (20% of the
overall ITT population); 235 received gefitinib and 107
TABLE 2. Ethnic Group of Patients of Asian Origin by Country of Residence
Ethnic group
Country Total (n [%]) Chinese Japanese
Asian (other than Chinese and
Japanese) Othera Not applicableb
Taiwan 108 (31.6) 108 0 0 0 0
Thailand 82 (24.0) 0 0 82 0 0
Singapore 51 (14.9) 48 0 3 0 0
Philippines 46 (13.5) 0 0 46 0 0
Malaysia 39 (11.4) 34 0 4 1 0
Australia 8 (2.3) 4 0 4 0 0
Brazil 3 (0.9) 1 1 0 0 1
United Kingdom 2 (0.6) 0 1 1 0 0
Canada 1 (0.3) 0 0 1 0 0
Mexico 1 (0.3) 0 1 0 0 0
Netherlands 1 (0.3) 0 0 1 0 0
Total (n [%]) 342 (100) 195 (57.0) 3 (0.9) 142 (41.5) 1 (0.3) 1 (0.3)
a Patient specified as Malay; b patient did not consider self as belonging to a specific ethnic group.
FIGURE 1. Overall survival in (A) patients of Asian origin
(B) patients of non-Asian origin.
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received placebo. Baseline demography was generally well
balanced between the treatment groups (Table 1). Al-
though there was a difference with respect to the number
of patients receiving one prior chemotherapy regimen
(53.6% gefitinib, 64.5% placebo), this was a small differ-
ence and was unlikely to have had a large effect on the
results because it was adjusted for in the statistical model.
Within this subset of patients of Asian origin, the ethnic
group of the majority of patients was Chinese or Asian
(other than Chinese and Japanese) [Table 2].
Survival in the Subset of Patients
of Asian Origin
The treatment-by-covariate interaction test was statis-
tically significant for the comparison of the outcome in
patients of Asian origin with the outcome in patients not of
Asian origin (p  0.0430). Therefore, further analyses of the
subset of patients of Asian origin were undertaken.
The preplanned subset analysis showed that gefitinib
significantly improved survival compared with placebo (HR,
0.66; 95% CI, 0.48, 0.91; p  0.010) [Figure 1A]. Median
survival was 9.5 months for gefitinib compared with
5.5 months for placebo, and the estimated 1-year survival
rates were 41 versus 23%, respectively. In patients of non-
Asian origin, there was no evidence of a difference in sur-
vival between treatment groups (HR, 0.92; 95% CI, 0.80,
1.07; p  0.294) [Figure 1B].
Covariate analyses of demographic subsets among pa-
tients of Asian origin treated with gefitinib showed a survival
advantage (HR1) across all subsets, although the margin of
benefit was slightly greater for never smokers (HR, 0.37; 95%
CI, 0.21, 0.64; p  0.0004) compared with smokers (HR,
0.85; 95% CI, 0.58, 1.25; p  0.4155), female patients (HR,
0.46; 95% CI, 0.26, 0.78; p  0.0045) compared with male
patients (HR, 0.80; 95% CI, 0.54, 1.19; p  0.2715), those
TABLE 3. Analysis of Overall Survival in Patient Subgroups Within the Subset of Patients of Asian Origin
n Deaths HRa 95% CI p valueb
All patients of Asian origin 342 173 0.66 0.48–0.91 0.0100
Histology
Adenocarcinoma 219 109 0.66 0.48–0.91 0.0028
Nonadenocarcinoma 123 64 0.86 0.50–1.47 0.5884
Smoking history
Never a smoker 141 54 0.37 0.21–0.64 0.0004
Smoker 201 119 0.85 0.58–1.25 0.4155
Reason for prior chemotherapy failure
Refractory 323 169 0.65 0.47–0.89 0.0077
Intolerant 19 4 n/a n/a n/a
Number of prior lines of chemotherapy
1 195 101 0.71 0.47–1.06 0.0955
2 147 72 0.66 0.40–1.09 0.1048
Performance status
0 or 1 247 108 0.78 0.52–1.16 0.2211
2 or 3 95 65 0.50 0.30–0.84 0.0088
Sex
Female 138 59 0.46 0.26–0.78 0.0045
Male 204 114 0.80 0.54–1.19 0.2715
Prior docetaxel treatment
Prior docetaxel treatment 94 46 0.75 0.39–1.45 0.3928
No prior docetaxel treatment 248 127 0.66 0.46–0.95 0.0253
Age
65 years 208 107 0.71 0.47–1.06 0.0917
65 years 134 66 0.69 0.41–1.16 0.1618
Diagnosis to randomization
6 months 92 55 0.50 0.27–0.92 0.0249
6–12 months 135 71 0.64 0.39–1.07 0.0875
12 months 115 47 0.75 0.39–1.42 0.3737
Prior response to chemotherapy
Complete response/partial response 72 32 0.55 0.26–1.17 0.1201
Stable disease 115 56 0.58 0.33–1.01 0.0530
Progressive disease/response not evaluated 155 85 0.84 0.53–1.33 0.4583
HR, hazard ratio; CI, confidence interval; a HR 1 implies a lower risk of death on gefitinib; b p values based on a Cox model; n/a, not applicable, too few events for statistical
analysis.
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with adenocarcinoma (HR, 0.54; 95% CI, 0.37, 0.81; p 
0.0028) versus those with nonadenocarcinoma (HR, 0.86;
95% CI, 0.50, 1.47; p  0.5884), or those at PS 2 or 3 (HR,
0.50; 95% CI, 0.30, 0.84; p  0.0088) compared with those
at PS 0 or 1 (HR, 0.78; 95% CI, 0.52, 1.16; p  0.2211)
[Table 3].
Because patients of Asian origin can comprise a number
of different ethnic groups, further post hoc data-driven analyses
were performed to determine HRs for survival in individual
ethnic groups within the subset of patients of Asian origin.
Only the Chinese (n  195) and Asian (other than Chinese
and Japanese; n  142) ethnic groups within this population
subset were large enough for this analysis, and HRs were
very similar between the two groups (0.69 and 0.63, respec-
tively).
TTF in the Subset of Patients of Asian Origin
Gefitinib significantly improved TTF compared with
placebo (HR, 0.69; 95% CI, 0.52, 0.91; p  0.0084)
[Figure 2]; median TTF were 4.4 and 2.2 months, respec-
tively. Disease progression (either radiographic or symp-
tomatic) was the most common reason for treatment failure
in the gefitinib and placebo arms (49.4 versus 64.5%,
respectively).
Objective Response in the Subset of Patients
of Asian Origin
Three hundred and six patients (209 receiving ge-
fitinib and 97 receiving placebo) were evaluable for tumor
response at baseline. Patients treated with gefitinib had a
higher response rate compared with placebo (12.4 versus
2.1%, respectively).
QoL and Disease-Related Symptoms in the
Subset of Patients of Asian Origin
Mean changes from baseline for FACT-L and lung
cancer subscale (LCS) scores favored gefitinib compared
with placebo (Figure 3). Despite a statistically significant
improvement in mean change from baseline LCS score for
gefitinib compared with placebo (0.39 versus 1.30, respec-
tively; p  0.0009), this difference failed to meet the criteria
for clinical relevance, which required an increase of at least
two points. There was less deterioration in mean FACT-L
scores with gefitinib than placebo, but this did not reach
statistical significance (0.13 versus 2.90; p  0.1623).
FACT-L and LCS improvement rates were higher in patients
treated with gefitinib compared with placebo (FACT-L, 37.8
versus 18.3%; LCS, 41.3 versus 23.2%).
Tolerability in the Subset of Patients
of Asian Origin
All 342 patients were evaluable for tolerability. In both
treatment groups, patients of Asian origin reported adverse
events more frequently than the overall population (96.6
versus 82.3% for gefitinib; 86.0 versus 70.6% for placebo).
Treatment with gefitinib was generally well tolerated (Table
4). The most common adverse events reported by patients of
Asian origin were rash (51.9 versus 15.0% for gefitinib and
placebo; including acne, eruptions, exanthems, rash pustular,
and dermatitis exfoliative) and diarrhea (33.2 versus 7.5% for
gefitinib and placebo). Grade 3/4 adverse events were ob-
served in 43.0% of patients receiving gefitinib and 35.5%
receiving placebo. The incidence of interstitial lung disease
(ILD)-type events was similar in patients of Asian origin
receiving gefitinib or placebo (3 versus 4%).
The frequency of adverse events leading to with-
drawal among patients of Asian origin was 7.2% for
gefitinib and 1.9% for placebo. Dose interruptions because
of adverse events were required in 11.5% of patients
receiving gefitinib and 3.7% of patients receiving placebo.
Serious adverse events leading to death occurred in 4.7%
of patients in the gefitinib-treatment group and 5.6% in the
placebo group.
DISCUSSION
In the overall ISEL population, gefitinib treatment was
not associated with significant improvement in survival14;
however, preplanned subset analyses revealed differing treat-
ment effects in patients who had never smoked compared
with those who had smoked (p  0.0474) and in patients of
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Asian origin compared with those of non-Asian origin (p 
0.0430).14 Therefore, further analyses were performed in
these subsets.
In patients of Asian origin from the ISEL trial, gefitinib
significantly reduced the risk of death by 34% and TTF by
31% compared with placebo. ORR was also improved in
patients of Asian origin treated with gefitinib compared with
placebo. Although the credibility of subset findings is always
a matter of debate, the potential for identifying subsets with
significant treatment effects in this study based on chance
alone was reduced by identification of subsets before unblind-
ing and through the use of rigorous statistical analysis using
treatment-by-covariate interactions. Therefore, the benefit ob-
served in patients of Asian origin with gefitinib is most likely
attributable to a real effect. Post hoc analyses of survival in
the Chinese and Asian (other than Chinese and Japanese)
ethnic groups suggested that there was no apparent difference
in treatment effect between these two groups.
Extensive experience has been gained with gefitinib in
Asian patients through the IDEAL 1 study, the Expanded
Access Programme, nonrandomized trials, and postmarketing
use (as of January 5, 2006, an estimated 75,525 patients in
Asia had been exposed to gefitinib [AstraZeneca, data on
file]). The ISEL data confirm previous observations from
Asia that greater benefit was experienced by patients of Asian
origin compared with patients of non-Asian origin, although
caution must be used when interpreting these previous reports
because patient numbers within each of these studies are
often low, and there is often no comparator arm (Figure
4).4,6–8,9,12,13,21,22 A Canadian study in which 38% of patients
were of Asian origin also suggests that response rates with
gefitinib are higher in those of Asian origin.23 The results
observed with gefitinib are supported by data from a phase III
trial comparing erlotinib with placebo in patients with refrac-
tory NSCLC (BR21),24 which also demonstrated increased
survival and response among patients of Asian origin. The
potential reasons for the increased effectiveness of EGFR-
TKIs in patients of Asian origin (and in never smokers) are
likely to be complex and the focus of much research.
Could patient demography have affected the efficacy of
gefitinib in patients of Asian origin in ISEL? The patient
demographics of the Asian subset were generally similar to
those of the overall ISEL population, but there were a few
potentially important differences between the two groups.
Compared with the overall ISEL population, a higher propor-
tion of patients of Asian origin were female (33 versus 40%),
had never smoked (22 versus 41%), and had adenocarcinoma
histology (45 versus 61%). Because all of these patient
subsets have previously been associated with increased ben-
TABLE 4. Adverse Events (All Common Toxicity Criteria [CTC] Grades) Occurring with an Incidence of 5% in Either
Treatment Group in Patients of Asian Origin
Percentage of evaluable patients
Gefitinib (n  235) Placebo (n  107)
Adverse eventa All CTC grades CTC grade 3–4 All CTC grades CTC grade 3–4
Rashb 51.9 1.7 15.0 0.0
Diarrhea 33.2 3.0 7.5 0.0
Dry skin 30.6 0.0 8.4 0.0
Anorexiac 27.2 2.6 18.7 0.0
Nausea 16.6 0.9 9.3 0.0
Pruritusd 17.0 0.0 6.5 0.0
Constipation 10.6 2.1 14.0 2.8
Dyspnoea 9.4 2.6 14.0 4.7
Pneumonia 9.4 6.4 13.1 9.3
Cough 8.1 0.4 12.1 0.9
Vomiting 11.9 0.9 10.3 0.0
Peripheral edema 2.6 0.0 10.3 0.9
Pyrexia 11.1 1.7 8.4 1.9
a Medical Dictionary for Regulatory Activities preferred term; b rash includes acne, eruptions, exanthems, rash pustular, and dermatitis exfoliative; c anorexia includes decreased
appetite and malnutrition; d pruritus includes pruritus, rash pruritic, and pruritus generalized.
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FIGURE 4. One-year survival rates of patients treated with
gefitinib in IRESSA Survival Evaluation in Lung Cancer (ISEL)
and other studies in Asian patients.
Journal of Thoracic Oncology • Volume 1, Number 8, October 2006 Gefitinib in Asian NSCLC Patients
Copyright © 2006 by the International Association for the Study of Lung Cancer 853
efit with gefitinib,4,5,22,23,25 the increased benefit in patients of
Asian origin might be attributable to a population effect. The
use of a comparator (placebo) arm in ISEL suggests that
Asian ethnicity predicts survival benefit with gefitinib over
placebo and is not just a prognostic factor for longer survival
regardless of treatment. Nevertheless, this analysis cannot
distinguish whether other overlapping predictive demo-
graphic factors are at least partially responsible for the in-
creased efficacy of gefitinib in patients of Asian origin com-
pared with patients of non-Asian origin. Thus, for patients of
Asian origin treated with gefitinib, it is difficult to say how
much benefit over placebo is attributable to their ethnicity or
to the fact that these patients tended to be female, to never
have smoked, and to have adenocarcinoma. It is worth noting
that median survival in patients who received placebo was
similar between the overall ISEL population (5.1 months) and
the subset of patients of Asian origin (5.5 months).
Improved responses to gefitinib have been associated with
overexpression or amplification of the EGFR gene.11,26,27 Acti-
vating EGFR mutations have also been shown to lead to
gefitinib responsiveness in NSCLC patients,11,26,28,29,30 per-
haps because of increased levels of gefitinib-induced apopto-
sis.31 Moreover, in NSCLC, EGFR mutations appear to occur
more frequently in patients of Asian ethnicity than in patients
of other ethnicities.29,32,33 The inclusion of a placebo-con-
trolled comparator arm in the ISEL study demonstrates that
the increased responsiveness to gefitinib in patients of Asian
origin is indeed a treatment-related effect. Nevertheless, it
remains unclear whether differences in the prevalence of
EGFR amplification or mutations within prognostic factors
(e.g., gender, smoking history, tumor histology) may prove to
be responsible, at least in part, for the differential advantage
of gefitinib over placebo between Asian and non-Asian pop-
ulations.
Consistent with previously reported studies,4,5,34 ge-
fitinib was well tolerated in the overall ISEL population.14 In
patients of Asian origin, a higher incidence of adverse events
was observed in the gefitinib group and the placebo group
compared with the overall population.14 Moreover, the in-
crease in adverse events in the placebo group indicates that
this is unlikely to be a treatment-related effect. These data are
consistent with other reports that have also noticed increased
adverse events being reported in Asian NSCLC patients
treated with gefitinib,6 and the incidence of ILD with gefitinib
seems to be higher in Japanese patients than in those from
other countries.35 In the overall ISEL population, the inci-
dence of ILD-type events was similar in the gefitinib and
placebo groups (1%) and slightly higher in patients of Asian
origin receiving gefitinib (3%) or placebo (4%), indicating
that the use of gefitinib did not result in an increased rate of
ILD in Asian patients in the ISEL study compared with
placebo.
In ISEL, the withdrawal rate attributable to adverse
events in patients of Asian origin versus that of the overall
population was similar for those receiving gefitinib
(7.2 versus 5.4%) and placebo (1.9 versus 2.3%), providing
further evidence that gefitinib is generally well tolerated in
patients of Asian origin, which is consistent with the known
safety profile of gefitinib.
In conclusion, for patients of Asian origin with ad-
vanced NSCLC who were refractory to or intolerant of their
most recent chemotherapy regimen, gefitinib at a dosage of
250 mg/day significantly increased survival and TTF and
appeared to improve response rates compared with placebo.
Phase III studies are currently underway comparing gefitinib
with single-agent docetaxel in the second- and third-line
setting, one of which (the Japanese trial V 15-32) is being
conducted in Japan. The results of this trial should help to
further elucidate the efficacy profile of gefitinib in patients of
Asian origin, and additional work in the first line and other
settings should help identify which patients in which treat-
ment settings are most likely to benefit from treatment with
gefitinib.
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